Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company earned $10 million in a...
Will Rapidly Advance Promising Drug Candidates to the Clinic SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its 2014 immuno-oncology collaboration with Celgene on four programs that are advancing through preclinical...
SAN FRANCISCO, Sept. 7, 2016 – Sutro Biopharma Inc. today announced that it has received two milestone payments from drug discovery and development partner Celgene Corporation (Celgene) for achievements in preclinical development and manufacturing under the company's...
Deal expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient Benefit SOUTH SAN FRANCISCO, Oct 23, 2014 – Sutro Biopharma today announced it has entered into a strategic...
SAN FRANCISCO, Dec. 18, 2012 - Sutro Biopharma today announced a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody....
STANLEY R. FRANKEL, M.D. Member, Scientific Advisory Board Dr. Frankel was most recently Chief Medical Officer at Cytovia. Previously, he was the Senior Vice President, Cellular Therapy Development at Bristol-Myers Squibb (BMS) where he was responsible for late...
SOUTH SAN FRANCISCO, Calif., June 3, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
SOUTH SAN FRANCISCO, Calif., June 2, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
- Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 - - Meetings with regulatory agencies for STRO-002 are planned for mid-year 2022 and near-final dose expansion data...
SOUTH SAN FRANCISCO, Calif., April 29, 2022 – Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to...
